Evidence map›Paper›PMID 29181857›Full record

ArticleNeuropathology and applied neurobiology2018

Whole-exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer's disease.

T Patel, K J Brookes, J Turton, S Chaudhury, T Guetta-Baranes, R Guerreiro, J Bras, D Hernandez, A Singleton, P T Francis and 2 more

Open access · greenAbstract read
In one paragraph

Article in Neuropathology and applied neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The relationship of early- and late-onset Alzheimer's disease genes with COVID-19.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

T PatelHuman Genetics Group, University of Nottingham, Nottingham, UK.ORCID 0000-0002-2797-1443
K J BrookesHuman Genetics Group, University of Nottingham, Nottingham, UK.
J TurtonHuman Genetics Group, University of Nottingham, Nottingham, UK.
S ChaudhuryHuman Genetics Group, University of Nottingham, Nottingham, UK.
T Guetta-BaranesHuman Genetics Group, University of Nottingham, Nottingham, UK.
R GuerreiroDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
J BrasDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
D HernandezLaboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD, USA.
A SingletonLaboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD, USA.
P T FrancisBrains for Dementia Research Resource, Wolfson Centre for Age Related Diseases, King's College London, London, UK.
J HardyDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
K MorganHuman Genetics Group, University of Nottingham, Nottingham, UK.
University of Nottingham · GBUK Dementia Research Institute · GBNational Institute on Aging · USKing's College London · GB

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
Characterization of Normal Genomic VariabilityZIAAG000932 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$11.3M
CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
Genetic Analysis Of Alzheimer s DiseaseZIAAG000950 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2019
$6.9M
Genetic Analysis Of Non- Alzheimer's disease DementiasZIAAG000951 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2020
$5.6M
Collaborative GWAS of Dementia, AD and related MRI and Cognitive EndophenotypesR01AG033193 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SESHADRI, SUDHA · 2009 to 2016
$4.4M
Genetic Analysis Of Alzheimer's DiseaseZ01AG000950 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2002 to 2008
$1.0M
Genetic Analysis Of Non-Alzheimer DementiasZ01AG000951 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2002 to 2008
$647k
Alzheimer's Research UKAlzheimer's SocietyBrains for Dementia Research (BDR)French National FoundationIntramural NIH HHS Z01 AG000950Intramural NIH HHS Z01 AG000951Intramural NIH HHS Z99 AG999999Medical Research Council G0400074Medical Research Council G0701075Medical Research Council MR/L022656/1NHLBI NIH HHS R01 HL105756NIA NIH HHS R01 AG033193NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG032984NIA NIH HHS U24 AG021886Parkinson's UK G-0907UK Medical Research Council G0400074Wellcome Trust
6 · The paper itself

Abstract

aimLate-onset Alzheimer's disease (LOAD) accounts for 95% of all Alzheimer's cases and is genetically complex in nature. Overlapping clinical and neuropathological features between AD, FTD and Parkinson's disease highlight the potential role of genetic pleiotropy across diseases. Recent genome-wide association studies (GWASs) have uncovered 20 new loci for AD risk; however, these exhibit small effect sizes. Using NGS, here we perform association analyses using exome-wide and candidate-gene-driven approaches.

methodsWhole-exome sequencing was performed on 132 AD cases and 53 control samples. Exome-wide single-variant association and gene burden tests were performed for 76 640 nonsingleton variants. Samples were also screened for known causative mutations in familial genes in AD and other dementias. Single-variant association and burden analysis was also carried out on variants in known AD and other neurological dementia genes.

resultsTentative single-variant and burden associations were seen in several genes with kinase and protease activity. Exome-wide burden analysis also revealed significant burden of variants in PILRA (P = 3.4 × 10

conclusionsIn addition, polygenic risk scores (PRS) were able to distinguish between cases and controls with 83.8% accuracy using 3268 variants, sex, age at death and APOE ε4 and ε2 status as predictors.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseCohort StudiesExome SequencingFemaleGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansMaleMembrane GlycoproteinsMultifactorial InheritanceReceptors, ImmunologicMembrane GlycoproteinsPILRA protein, humanReceptors, ImmunologicAlzheimer's diseaseburden analysispolygenic risk scoreWhole-exome sequencing

Identifiers

PMID29181857
PMCPMC6005734
OpenAlexW2770093837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.